Search
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnFood and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersGrowth/differentiation factor 15
go.drugbank.com/bio_entities/BE0010537TargetHumansHormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite (PubMed:23468844, PubMed:24971956, Pub...
Polypeptides: Growth/differentiation factor 15Synonyms: GDF-15Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]
Categories: Compounds used in a research, industrial, or household settingVaricella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalpatients 50-70 years of age [FDA Label]. … First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as
Potassium cation
go.drugbank.com/drugs/DB01345ApprovedThe cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. … The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential.
Mixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 150 ML (PVC TORBA) SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 150 ML (PVC TORBA) SETSİZBrimapitide
go.drugbank.com/drugs/DB15231InvestigationalBrimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345].
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter [L1858]. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). … CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.